<DOC>
	<DOC>NCT01593735</DOC>
	<brief_summary>This is a multiple dose study of the safety and efficacy of MK-2748 to be done in 2 Parts. Part I will enroll genotype 1 (GT1) hepatitis C virus (HCV)-infected participants and Part II will enroll genotype 3 (GT3) HCV-infected participants. Both Parts may run concurrently or may be staggered.</brief_summary>
	<brief_title>A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Inclusion criteria: Clinical diagnosis of chronic HCV infection (GT1 or GT3) for at least 6 months and detectable HCVRNA in peripheral blood Body mass index (BMI) of 18 to 37 kg/m^2 No clinically significant abnormality on electrocardiogram (ECG) Stable health Willing to use appropriate contraception throughout the study and for 90 days after last dose of study drug Exclusion criteria: Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study History of stroke, chronic seizures, or major neurological disorder History of clinically significant endocrine, gastrointestinal (excepting HCV infection), cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases History of neoplastic disease (exceptions of adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix, or other malignancies which have been successfully treated ≥10 years prior and unlikely to recur Positive Hepatitis B surface antigen Documented human immunodeficiency virus (HIV) infection Consumption of excessive amounts of alcohol, defined as greater than 2 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces],wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day Consumption of excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) or coffee, tea, cola, or other caffeinated beverages per day Major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to study enrollment History of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food Current regular user (including "recreational use") of any illicit drugs or history of drug (including alcohol) abuse within approximately 2 months prior to enrollment Evidence or history of chronic hepatitis not caused by HCV including but not limited to nonHCV viral hepatitis, nonalcoholic steatohepatitis (NASH), drug induced hepatitis, autoimmune hepatitis Previous treatment with other HCV NS3/4A protease inhibitors Previous exposure to interferonalpha and/or ribavirin within 3 months prior to study enrollment Clinical or laboratory evidence of advanced or decompensated liver disease; evidence of bridging fibrosis or higher grade fibrosis (Metavir score ≥3) Participation in another investigational study within 4 weeks prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>